SAR441169
/ Sanofi, Lead Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 28, 2021
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
(GlobeNewswire)
- "Development of SAR441169, ROR gamma T antagonist in collaboration with Lead Pharma, was terminated in psoriasis."
Discontinued • Immunology • Psoriasis
1 to 1
Of
1
Go to page
1